Innovations in GLP-1 Receptor Agonist Therapy: Patient-Centered Strategies to Overcome Barriers and Reduce Cardiometabolic Risk in T2DM

Release date: September 27 2019
Expiration date: September 27, 2020
Estimated time to complete activity: 1.0 hour(s)

 

 

FACULTY

Vivian A. Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Tullis–Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

 

Richard E. Pratley, MD
Director
Florida Hospital Diabetes Institute
Senior Scientist
Translational Research Institute for Metabolism and Diabetes
Orlando, Florida

PROGRAM OVERVIEW

To address the cardiovascular (CV) morbidity and mortality risks associated with Type 2 Diabetes Mellitus (T2DM), national guidelines now recommend the use of antidiabetic agents that have shown improvement in CV outcomes in clinical trials, including GLP-1 Receptor Agonists (RAs). Despite the benefits of these agents to patients with T2DM, recent data indicate a nationwide shortage in endocrinologists and geographically-related barriers to care may threaten the progress these agents have made in diabetes management. To meet the needs of patients with T2DM, the role of family practitioners (FPs) has expanded to fill the demand; however, FPs require education on the place of GLP-1 RAs in the management of diabetes, including pharmacokinetic/pharmacodynamic mechanisms, safety and efficacy data, Cardiovascular Outcome Trial (CVOT) outcomes, and patient satisfaction and adherence to fully embrace this evolving role. The extension of antidiabetic therapy beyond glycemic control has led to a paradigm shift in the management of T2DM. As a result, FPs must be prepared to take on a larger role in patient care. This activity will provide knowledge to address these educational needs among primarycare providers (PCPs), and application of this knowledge will improve outcomes for patients with T2DM.

TARGET AUDIENCE

This educational initiative has been designed for family physicians involved in the diagnosis and management of T2DM.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Explain geographic trends in access to endocrinologists and define the critical role of PCPs in the management of T2DM
  • Compare the underlying pathophysiological mechanisms and pharmacokinetic/pharmacodynamic profiles for currently available and emerging GLP-1 RA agents
  • Evaluate updated guideline recommendations and the clinical trial data on the efficacy and safety of specific GLP-1 RAs, in addition to recent CVOT, patient satisfaction, and adherence data
  • Identify common provider and patient-related barriers so that GLP-1 RAs can be introduced to more effectively control glucose, improve cardiometabolic risk factors, and increase patient satisfaction and adherence
  • Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 27, 2019 through September 27, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

PHYSICIAN CONTINUING MEDICAL EDUCATION ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Vivian A. Fonseca, MD, FRCP

Consulting Fees: Abbott; Asahi; AstraZeneca Pharmaceuticals LP; Lilly; Intarcia; Novo Nordisk Pharmaceuticals; Sanofi US; Takeda Pharmaceuticals U.S.A., Inc.
Contracted Research: Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.
Ownership Interest: Amgen; BRAVO4Health; Insulin Algorithms; Mircobiome Technologies

Richard E. Pratley, MD
Consulting Fees: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Glytec, LLC; Janssen Scientific Affairs, LLC; Ligand Pharmaceuticals, Inc.; Lilly; Merck; Mundipharma; Novo Nordisk Pharmaceuticals; Pfizer; Sanofi US
Speakers Bureau: Novo Nordisk Pharmaceuticals
Contracted Research: Lexicon Pharmaceuticals; Ligand Pharmaceuticals, Inc.; Lilly; Merck; Novo Nordisk Pharmaceuticals; Sanofi US

Patima Tanapat hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Novo Nordisk Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Novo Nordisk Pharmaceuticals.

Continue to Pretest